Human Breast Tumor-Associated Endothelial Cells

Cat.No.: CSC-C8582W

Species: Human

Source: Breast

Cell Type: Endothelial Cell

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C8582W
Description
Human Breast Tumor-Associated Endothelial Cells from Creative Bioarray are isolated from human breast tumor tissue. Human Breast Tumor-Associated Endothelial Cells are grown in T25 tissue culture flasks pre-coated with gelatin-based solution for 2 min and incubated in Creative Bioarray’ Culture Complete Growth Medium generally for 3-7 days. Cultures are then expanded. The method we use to isolate endothelial cells was developed based on a combination of established and our proprietary methods. These cells are pre-coated with PECAM-1 antibody, following the application of magnetic beads pre-coated with secondary antibody.
Species
Human
Source
Breast
Cell Type
Endothelial Cell
Disease
Breast Cancer; Cancer
Quality Control
Human Breast Tumor-Associated Endothelial Cells from Creative Bioarray display typical cobblestone with large dark nuclei appearance under light microscopy. Cells are tested for expression of endothelial cell marker using antibody, CD31 (Catalog No. 550389, BD; CD31/PECAM-1 PE-conjugated Antibody, Catalog No. FAB3567P, R&D) or VE-Cadherin (FITC-VE-cadherin Catalog No. 560411, BD) by immunofluorescence staining or FACS. All cells test negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C are not detected for all donors and/or cell lots. Per request, a Certificate of Analysis will be provided for each cell lot purchased. Cells can be expanded for 3-5 passages under the cell culture conditions specified by Creative Bioarray. Repeated freezing and thawing of cells is not recommended.
Storage and Shipping
Creative Bioarray ships frozen cells on dry ice. On receipt, immediately transfer frozen cells to liquid nitrogen (-180 °C) until ready for experimental use. Live cell shipment is also available on request. Never can primary cells be kept at -20 °C.
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Human Breast Tumor Associated Endothelial Cells (HBTAECs) are primary endothelial cells isolated from the vasculature of human breast tumor tissues. HBTAECs are not similar to the normal endothelial cells, but they show the specific biological and functional features of the tumor microenvironment, such as increased angiogenesis, abnormal vascular organization and altered gene expression profiles. These cells usually express canonical endothelial markers such as CD31, VE-cadherin and von Willebrand factor (vWF) but also demonstrate increased expression of pro-angiogenic factors including VEGFR2 and heightened sensitivity to tumor-derived signals. HBTAECs were more proliferative, migratory and tube-forming than endothelial cells derived from normal tissues adjacent to the tumors. They also exhibit unique metabolic adaptations and increased resistance to anti-angiogenic therapies, which makes them extremely relevant to the study of therapeutic resistance. Importantly, these cells actively cross-talk with cancer cells, immune cells and stromal components, leading to tumor progression, metastasis and immune modulation.

HBTAECs, due to their tumor-specific phenotype, represent a physiologically relevant in vitro model for investigating breast cancer angiogenesis, vascular permeability and drug delivery mechanisms. They are widely used in anti-angiogenic drug screening, nanomedicine targeting studies and tumor microenvironment research. Overall, HBTAECs are useful platform to understand the intricacies of tumor vasculature and develop more effective targeted cancer therapies.

Tumor-Associated Endothelial Cells Favor Interactions with Administered Nanoparticles

Cancer nanomedicines rely on endothelial cells for tumor delivery, but their translational relevance in humans is unclear. Using primary human breast cancer endothelial cells (HBTECs), Wang et al. quantified the differential interactions of normal versus tumor-associated endothelial cells with three clinically relevant nanomedicines: PEGylated gold nanoparticles, liposomal doxorubicin, and LNPs.

Across all tested conditions-including standard media, conditioned media, and human serum-HBTECs exhibited significantly stronger interactions with gold nanoparticles than normal controls (HMMECs, HUVECs), reaching up to ~1.9-fold higher uptake (Fig. 1a-c). No significant difference was observed between general and conditioned media.

Similarly, confocal microscopy revealed greater intracellular fluorescence in HBTECs following incubation with liposomal doxorubicin or DiO-LNPs (Fig. 1d, f). Quantitative image analysis confirmed higher uptake per cell and per cell area in HBTECs (Fig. 1e, g).

These findings were consistent across nanoparticles with varying sizes (~70-90 nm) and stiffness. Collectively, our data demonstrate that tumor-associated endothelial cells exhibit enhanced interactions with diverse nanomedicines compared to normal endothelial cells.

Breast tumor-associated endothelial cells favor interactions with nanoparticles.

Fig. 1. Breast tumor-associated endothelial cells favor interactions with nanoparticles (Wang L, Sheth V, et al., 2024).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products